Selective mass treatment of STIs may lead to a durable reduction in the prevalence of STIs or a temporary reduction associated with an increased probability of antimicrobial resistance emerging.
Methods
We searched PubMed and Google Scholar for studies evaluating the impact of mass STI treatment on the long-term prevalence of chlamydia, gonorrhoea, syphilis and chancroid. The primary outcomes were the long term (≥3 months post the intervention) impact of the intervention on prevalence/incidence of the STI and on antimicrobial resistance.
Results
Our search yielded 269 studies, of which 4 met the inclusion criteria. With the exception of the Carletonville study, where this was not assessed, three of the four studies found that intensive STI treatment was associated with a reduced prevalence of the targeted STI during or immediately after the intervention. In all four studies, there was no evidence that the intense treatment had a long-term effect on prevalence. In the only study where this was assessed, the intensive use of penicillin to reduce gonococcal prevalence was associated with the emergence of reduced susceptibility to penicillin in N. gonorrhoeae.
Conclusion
The available evidence suggests that mass treatment of chlamydia, gonorrhoea and syphilis in high prevalence populations is only associated with a temporary reduction in the prevalence of these infections and may select for antimicrobial resistance.
SealeABroutetNNarasimhanM. Assessing process, content, and politics in developing the global health sector strategy on sexually transmitted infections 2016–2021: implementation opportunities for policymakers. PLoS Med2017; 14(6): e1002330.
2.
FuLSunYHanM, et al.Incidence trends of five common sexually transmitted infections excluding HIV from 1990 to 2019 at the global, regional, and national levels: results from the Global Burden of Disease Study 2019. Front Med2022; 9: 851635.
3.
KongFYSKenyonCUnemoM. Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections. J Antimicrob Chemother. 2023; 78(7): 1561–1568. DOI: 10.1093/jac/dkad129.
4.
SteenRChersichMGerbaseA, et al.Periodic presumptive treatment of curable sexually transmitted infections among sex workers: a systematic review. AIDS2012; 26(4): 437–445.
5.
MolinaJ-MCharreauIChidiacC, et al.Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis2018; 18(3): 308–317.
6.
LuetkemeyerAFDonnellDDombrowskiJC, et al.Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med2023; 388(14): 1296–1306.
7.
LowNBenderNNarteyL, et al.Effectiveness of chlamydia screening: systematic review. Int J Epidemiol2009; 38(2): 435–448.
8.
JennessSMWeissKMGoodreauSM, et al.Incidence of gonorrhea and Chlamydia following HIV preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis. 2017; 65(5): 712–718. DOI: 10.1093/cid/cix439.
9.
TsoumanisAVan DijckCHensN, et al.Rethinking screening intensity in terms of reducing prevalence or increasing selection pressure for the emergence of resistant gonorrhea: a modeling study of men who have sex with men in Belgium. Open Forum Infect Dis. 2023; 10(4): ofad165. DOI: 10.1093/ofid/ofad165.
10.
TsoumanisAHensNKenyonCR. Is screening for chlamydia and gonorrhea in men who have sex with men associated with reduction of the prevalence of these infections? A systematic review of observational studies. Sex Transm Dis2018; 45(9): 615–622.
11.
Zalmanovici TrestioreanuAFraserAGafter-GviliA, et al.Antibiotics for preventing meningococcal infections. Department of Family Medicine, Israel. Update of Cochrane Database Syst Rev, 2006.
12.
BealeMANoguera-JulianMGodornesC, et al.Yaws re-emergence and bacterial drug resistance selection after mass administration of azithromycin: a genomic epidemiology investigation. The Lancet Microbe2020; 1(6): e263–e271.
13.
ChessonHWMayaudPAralSO. Sexually transmitted infections: impact and cost-effectiveness of prevention. In: Major infectious diseases. 3rd ed.Washington (DC): The International Bank for Reconstruction and Development/The World Bank, 2017.
14.
KenyonCRSchwartzIS. Effects of sexual network connectivity and antimicrobial drug use on antimicrobial resistance in Neisseria gonorrhoeae. Emerg Infect Dis. 2018; 24(7): 1195–1203. DOI: 10.3201/eid2407.172104.
15.
KenyonCRDelvaW. It’s the network, stupid: a population’s sexual network connectivity determines its STI prevalence. F1000Research. 2018; 7: PMC6376253. DOI: 10.12688/f1000research.17148.2.
16.
MolinaJ-MGhosnJAssoumouL, et al.Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. The lancet HIV2022; 9(8): e554–e562.
17.
HopkinsDR. Control of yaws and other endemic treponematoses: implementation of vertical and/or integrated programs. Clin Infect Dis1985; 7(Supplement_2): S338–S342.
18.
KamaliAQuigleyMNakiyingiJ, et al.Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet2003; 361(9358): 645–652.
19.
WawerMJSewankamboNKSerwaddaD, et al.Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Lancet1999; 353(9152): 525–535.
20.
GrosskurthHToddJMwijarubiE, et al.Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet1995; 346(8974): 530–536.
21.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg2021; 88: 105906.
22.
OlsenGA. Epidemiological measures against gonorrhoea. Experience in Greenland. Br J Vener Dis. 1973; 49(2): 130–133. DOI: 10.1136/sti.49.2.130.
23.
OlsenGA. Consumption of antibiotics in Greenland, 1964-70. IV. Changes in the sensitivity of N. gonorrhoeae to antibiotics. Br J Vener Dis. 1973; 49(1): 33–41. DOI: 10.1136/sti.49.1.33.
24.
OlsenGA. Consumption of antibiotics in Greenland, 1964-1970. I. Economic and epidemiological considerations. Br J Vener Dis1973; 49(1): 20.
25.
RekartMLPatrickDMChakrabortyB, et al.Targeted mass treatment for syphilis with oral azithromycin. Lancet2003; 361(9354): 313–314.
26.
HolmesKKJohnsonDWKvalePA, et al.Impact of a gonorrhea control program, including selective mass treatment, in female sex workers. JID (J Infect Dis)1996; 174(Supplement_2): S230–S329.
27.
OlsenGA. Consumption of antibiotics in Greenland, 1964-70. 3. Effect of coincidental administration of antibiotics on gonorrhoeal infections. Br J Vener Dis. 1973; 49(1): 30–32. DOI: 10.1136/sti.49.1.30.
28.
NdhlovuLSearleCvan DamJ, et al.Reducing the transmission of HIV and sexually transmitted infections in a mining community: findings from the Carletonville Mothusimpilo intervention project: 1998 to 2001. In: Horizons final report. Washington, DC: Population Council, 2005.
29.
SteenRVuylstekeBDecoitoT, et al.Evidence of declining STD prevalence in a South African mining community following a core-group intervention. Sex Transm Dis. 2000; 27: 1–8.
30.
KenyonCROsbakKTsoumanisA. The global epidemiology of syphilis in the past century - a systematic review based on antenatal syphilis prevalence. PLoS Neglected Trop Dis2016; 10(5): e0004711, DOI: 10.1371/journal.pntd.0004711
31.
WilliamsEWilliamsonDAHockingJS. Frequent screening for asymptomatic chlamydia and gonorrhoea infections in men who have sex with men: time to re-evaluate?Lancet Infect Dis. 2023; 23(12): E558–E566.
32.
BerntsenSKarlsenAPHPedersenML, et al.Gonorrhoea in Greenland, incidence and previous preventive measures: a review to improve future strategies. Int J Circumpolar Health2017; 76(1): 1350092.
33.
UnemoMShaferWM. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann N Y Acad Sci2011; 1230(1): E19–E28.
34.
VanbaelenTTsoumanisAFlorenceE, et al.Does screening for Neisseria gonorrhoeae and Chlamydia trachomatis affect the incidence of these infections in men who have sex with men taking HIV pre-exposure prophylaxis (PrEP)? Results from a randomized, multicentre controlled trial (the Gonoscreen study). The Lancet HIV. 2023; 2023. DOI: 10.1016/S2352-3018(23)00299-0.
35.
KenyonC. Dual azithromycin/ceftriaxone therapy for gonorrhea in PrEP cohorts results in levels of macrolide consumption that exceed resistance thresholds by up to 7-fold. J Infect Dis2021; 224(9): 1623–1624.
36.
KenyonCBaetselierIDWoutersK. Screening for STIs in PrEP cohorts results in high levels of antimicrobial consumption. Int J STD AIDS2020; 31(12): 1215–1218.
37.
LewisDA. The role of core groups in the emergence and dissemination of antimicrobial-resistant N gonorrhoeae. Sex Transm Infect2013; 89(4): 47–51, DOI: 10.1136/sextrans-2013-051020
38.
UnemoMKongFYS. Doxycycline-PEP—novel and promising but needs monitoring. Nat Rev Urol. 2023; 20: 1–2.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
